A Protein Inhibitor Of Cas9

Tech ID: 29638 / UC Case 2019-008-0

Patent Status

Country Type Number Dated Case
Patent Cooperation Treaty Published Application WO2020055748 03/19/2020 2019-008
 

Additional Patent Pending

Brief Description


 

Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)/Cas9 nucleases, when complexed with a guide RNA, effect genome editing in a sequence-specific manner. RNA-guided Cas9 has proven to be a versatile tool for genome engineering in multiple cell types and organisms.  There is a need in the art for additional compositions and methods for controlling genome editing activity of CRISPR/Cas9.

 

UC Berkeley researchers have discovered a new protein that is able to inhibit the Cas9 protein from

Staphyloccocus aureus (SauCas9). SauCas9 is smaller than the frequently used Cas9 from Streptococcus pyogenes, which has a number of benefits for delivery. The inhibitor is a small protein from a phage and is capable of strongly inhibiting gene editing in human cells.

Suggested uses


  • Gene editing

Advantages


  • Limiting off-target editing, or other applications where reduced activity or rapid inhibition is desired

 

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Doudna, Jennifer A.

Other Information

Categorized As

Additional Technologies by these Inventors